Skip to main content

Table 1 Patient characteristics

From: The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia

  Analysis 1 Analysis 2 Analysis 3
Pre-treatment, n = 103 Control, n = 39 p value Pre-treatment, n = 103 Post-treatment, n = 103 p value Post-treatment, n = 103 Control, n = 39 p value
Age, years    0.0573    0.4131    0.0130
 Mean (SD, range) 31.9 (5.2, 25–45) 30.1 (4.4, 20–43)   31.9 (5.2, 25–45) 32.5 (5.3, 25–46)   32.5 (5.3, 25–46) 30.1 (4.4, 20–43)  
Ethnicity, n/N (%)    0.0659    > 0.9999    0.0659
 Caucasian 87/103 (85) 30/39 (77)   87/103 (85) 87/103 (85)   87/103 (85) 30/39 (77)  
 Asian 10/103 (10) 2/39 (5)   10/103 (10) 10/103 (10)   10/103 (10) 2/39 (5)  
 Black 6/103 (5) 7/39 (18)   6/103 (5) 6/103 (5)   6/103 (5) 7/39 (18)  
Parity, n/N (%)    0.5329    > 0.9999    0.5329
 Nulliparous 73/103 (71) 30/39 (76)   73/103 (71) 73/103 (71)   73/103 (71) 30/39 (76)  
 Parous 30/103 (29) 9/39 (24)   30/103 (29) 30/103 (29)   30/103 (29) 9/39 (24)  
Smoking status, n/N (%)    0.1909    > 0.9999    0.2647
 Current smoker 27/103 (26) 6/39 (15)   27/103 (26) 26/103 (25)   26/103 (25) 6/39 (15)  
 Non-smoker 76/103 (74) 33/39 (85)   76/103 (74) 77/103 (75)   77/103 (75) 33/39 (85)  
Phase of menstrual cycle, n/N (%)    0.6472    0.4655    0.5388
 Luteal 55/103 (53) 23/39 (58)   55/103 (53) 50/103 (48)   50/103 (48) 23/39 (58)  
 Follicular 38/103 (37) 14/39 (36)   38/103 (37) 46/103 (46)   46/103 (46) 14/39 (36)  
 Unknown 10/103 (10) 2/39 (5)   10/103 (10) 7/103 (7)   7/103 (7) 2/39 (5)  
Contraception, n/N (%)    0.7316    0.9982    0.6958
 Nil 35/103 (34) 19/39 (49)   35/103 (34) 34/103 (33)   34/103 (33) 19/39 (49)  
 Condoms 17/103 (16) 5/39 (13)   17/103 (16) 18/103 (17)   18/103 (17) 5/39 (13)  
 COCP 37/103 (36) 12/39 (31)   37/103 (36) 37/103 (36)   37/103 (36) 12/39 (31)  
 POP 5/103 (5) 1/39 (2)   5/103 (5) 5/103 (5)   5/103 (5) 1/39 (2)  
 Copper IUD 2/103 (2) 0/39 (0)   2/103 (2) 1/103 (1)   1/103 (1) 0/39 (0)  
 Mirena IUS 5/103 (5) 1/39 (2)   5/103 (5) 6/103 (6)   6/103 (6) 1/39 (2)  
 Contraceptive implant 2/103 (2) 1/39 (2)   2/103 (2) 2/103 (2)   2/103 (2) 1/39 (2)  
Time since last intercourse, n/N (%)    0.7684    > 0.9999    0.7684
 > 48 h 92/103 (89) 34/39 (87)   92/103 (89) 92/103 (89)   92/103 (89) 34/39 (87)  
 < 48 h 11/103 (11) 5/39 (13)   11/103 (11) 11/103 (11)   11/103 (11) 5/39 (13)  
HPV status     
 Negative    82/103 (80) 23/39 (59)  
 Positive    21/103 (20) 12/39 (31)  
 Unknown    0/103 (0) 4/39 (10)  
Cytology          
 Negative    81/103 (79) 39/39 (100)  
 Borderline nuclear changes    17/103 (16) 0/39 (0)  
 LSIL    3/103 (3) 0/39 (0)  
 HSIL    2/103 (2) 0/39 (0)  
Cytology and HPV status     
 Normal, HPV-ve    70/103 (69) 23/39 (59)  
 Normal, HPV+ve    11/103 (10) 12/39 (31)  
 Normal, HPV status unknown    0/103 (0) 4/39 (10)  
 BNC, HPV-ve   12/103 (11)   12/103 (11) 0/39 (0)  
 BNC, HPV+ve   5/103 (5)   5/103 (5) 0/39 (0)  
 LSIL, HPV-ve   0/103 (0)   0/103 (0) 0/39 (0)  
 LSIL, HPV+ve   3/103 (3)   3/103 (3) 0/39 (0)  
 HSIL   2/103 (2)   2/103 (2) 0/39 (0)  
  1. BNC borderline nuclear changes, CIN cervical intraepithelial neoplasia, COCP combined oral contraceptive pill, HSIL high-grade squamous intraepithelial neoplasia, HPV human papillomavirus, IUD intrauterine device, IUS intrauterine system, LSIL low-grade squamous intraepithelial neoplasia, POP progesterone-only pill, SD standard deviation